Aptinyx Inc. (NASDAQ:APTX) has been assigned a consensus suggestion of “Purchase” from the ten rankings corporations which can be presently protecting the corporate, Marketbeat reviews. Two analysis analysts have rated the stock with a maintain score and eight have issued a purchase score on the corporate. The typical 1-year price goal amongst brokerages which have issued a report on the stock within the final 12 months is $11.67.
Quite a lot of equities analysis analysts have just lately weighed in on the corporate. Cantor Fitzgerald lifted their goal price on Aptinyx from $9.00 to $12.00 and gave the stock an “obese” score in a report on Wednesday, October 28th. Cowen reissued a “purchase” score on shares of Aptinyx in a report on Wednesday, October 21st. William Blair reissued a “purchase” score on shares of Aptinyx in a report on Thursday, October 1st. JPMorgan Chase & Co. assumed protection on Aptinyx in a report on Wednesday, October 14th. They set a “impartial” score for the corporate. Lastly, HC Wainwright lifted their goal price on Aptinyx from $7.00 to $8.00 and gave the stock a “purchase” score in a report on Thursday, November 19th.
In associated information, main shareholder Bain Capital Life Sciences Inv bought 3,333,333 shares of the agency’s stock in a transaction that occurred on Monday, October 26th. The shares have been purchased at a median price of $3.00 per share, for a complete transaction of $9,999,999.00. The acquisition was disclosed in a doc filed with the Securities & Alternate Fee, which is accessible by way of the SEC web site. 8.58% of the stock is presently owned by firm insiders.
Quite a lot of institutional buyers have just lately added to or diminished their stakes within the enterprise. Two Sigma Advisers LP grew its place in Aptinyx by 5.0% within the second quarter. Two Sigma Advisers LP now owns 105,800 shares of the corporate’s stock valued at $441,000 after buying an extra 5,000 shares over the last quarter. UBS Group AG grew its place in Aptinyx by 2,549.0% within the second quarter. UBS Group AG now owns 7,947 shares of the corporate’s stock valued at $33,000 after buying an extra 7,647 shares over the last quarter. Public Workers Retirement System of Ohio purchased a brand new place in Aptinyx within the second quarter valued at about $37,000. Leap Investments LP purchased a brand new place in Aptinyx within the second quarter valued at about $58,000. Lastly, American Worldwide Group Inc. acquired a brand new stake in shares of Aptinyx through the second quarter valued at about $63,000. Hedge funds and different institutional buyers personal 59.13% of the corporate’s stock.
Shares of Aptinyx stock opened at $3.42 on Thursday. The enterprise has a fifty day easy transferring common of $3.34 and a two-hundred day easy transferring common of $3.72. Aptinyx has a 1 12 months low of $1.60 and a 1 12 months excessive of $6.47. The corporate has a market capitalization of $216.34 million, a price-to-earnings ratio of -2.71 and a beta of 1.23.
Aptinyx (NASDAQ:APTX) final posted its earnings outcomes on Tuesday, November 17th. The corporate reported ($0.24) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.06. Aptinyx had a detrimental return on fairness of 46.43% and a detrimental internet margin of two,108.05%. As a bunch, sell-side analysts count on that Aptinyx will submit -1.09 EPS for the present 12 months.
Aptinyx Inc, a clinical-stage biopharmaceutical firm, focuses on the invention, growth, and commercialization of novel, proprietary, and artificial small molecules for the therapy of mind and nervous system problems. The corporate is creating NYX-2925, which is in Section II medical growth for the therapy of painful diabetic peripheral neuropathy, in addition to in Section II medical trial for treating fibromyalgia.
Featured Article: Momentum Indicator: Relative Energy Index
This on the spot information alert was generated by narrative science know-how and monetary knowledge from MarketBeat so as to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to [email protected]